Nanosonics Ltd (NAN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nanosonics Ltd (NAN) has a cash flow conversion efficiency ratio of 0.109x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$22.81 Million ≈ $16.14 Million USD) by net assets (AU$209.91 Million ≈ $148.52 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nanosonics Ltd - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Nanosonics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Nanosonics Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Nanosonics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nanosonics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Intellian Technologies Inc
KQ:189300
|
0.042x |
|
BIOCYTOGEN PHARMA. H YC1
F:I54
|
N/A |
|
Gansu Golden Glass Technologies Co Ltd
SHE:300093
|
0.043x |
|
Shenzhen Sea Star Technology
SHE:002137
|
0.031x |
|
Korea Investment Holdings Co Ltd
KO:071055
|
-0.587x |
|
Regional Container Lines Public Company Limited
BK:RCL-R
|
0.054x |
|
Ningbo Techmation Co Ltd
SHG:603015
|
-0.006x |
|
CEWE Stiftung & Co. KGaA
XETRA:CWC
|
-0.010x |
Annual Cash Flow Conversion Efficiency for Nanosonics Ltd (2007–2025)
The table below shows the annual cash flow conversion efficiency of Nanosonics Ltd from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Nanosonics Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$209.91 Million ≈ $148.52 Million |
AU$43.98 Million ≈ $31.12 Million |
0.210x | +67.58% |
| 2024-06-30 | AU$182.20 Million ≈ $128.92 Million |
AU$22.78 Million ≈ $16.12 Million |
0.125x | -12.12% |
| 2023-06-30 | AU$163.86 Million ≈ $115.94 Million |
AU$23.31 Million ≈ $16.50 Million |
0.142x | +194.74% |
| 2022-06-30 | AU$138.69 Million ≈ $98.13 Million |
AU$6.70 Million ≈ $4.74 Million |
0.048x | -10.54% |
| 2021-06-30 | AU$135.57 Million ≈ $95.92 Million |
AU$7.32 Million ≈ $5.18 Million |
0.054x | -70.55% |
| 2020-06-30 | AU$124.23 Million ≈ $87.90 Million |
AU$22.76 Million ≈ $16.11 Million |
0.183x | +317.98% |
| 2019-06-30 | AU$110.08 Million ≈ $77.89 Million |
AU$4.83 Million ≈ $3.41 Million |
0.044x | -54.11% |
| 2018-06-30 | AU$94.30 Million ≈ $66.73 Million |
AU$9.01 Million ≈ $6.37 Million |
0.096x | -49.14% |
| 2017-06-30 | AU$87.25 Million ≈ $61.74 Million |
AU$16.39 Million ≈ $11.60 Million |
0.188x | +230.12% |
| 2016-06-30 | AU$56.66 Million ≈ $40.09 Million |
AU$3.22 Million ≈ $2.28 Million |
0.057x | +204.99% |
| 2015-06-30 | AU$44.68 Million ≈ $31.61 Million |
AU$-2.42 Million ≈ $-1.71 Million |
-0.054x | +57.31% |
| 2014-06-30 | AU$20.43 Million ≈ $14.46 Million |
AU$-2.59 Million ≈ $-1.84 Million |
-0.127x | +38.85% |
| 2013-06-30 | AU$21.71 Million ≈ $15.36 Million |
AU$-4.51 Million ≈ $-3.19 Million |
-0.208x | -7.33% |
| 2012-06-30 | AU$26.00 Million ≈ $18.40 Million |
AU$-5.03 Million ≈ $-3.56 Million |
-0.193x | +69.26% |
| 2011-06-30 | AU$14.31 Million ≈ $10.12 Million |
AU$-9.00 Million ≈ $-6.37 Million |
-0.629x | -91.15% |
| 2010-06-30 | AU$23.58 Million ≈ $16.69 Million |
AU$-7.76 Million ≈ $-5.49 Million |
-0.329x | +41.23% |
| 2009-06-30 | AU$16.31 Million ≈ $11.54 Million |
AU$-9.14 Million ≈ $-6.46 Million |
-0.560x | -92.78% |
| 2008-06-30 | AU$24.56 Million ≈ $17.38 Million |
AU$-7.13 Million ≈ $-5.05 Million |
-0.291x | -98.38% |
| 2007-06-30 | AU$31.32 Million ≈ $22.16 Million |
AU$-4.59 Million ≈ $-3.25 Million |
-0.146x | -- |
About Nanosonics Ltd
Nanosonics Limited operates as an infection prevention company in Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific. The company manufactures and distributes trophon ultrasound probe disinfector, and its related consumables and accessories; and research, develops, and commercialize of infection control and decontamination products and related technologies. It… Read more